385 related articles for article (PubMed ID: 29848375)
1. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
Sullivan RJ; Atkins MB; Kirkwood JM; Agarwala SS; Clark JI; Ernstoff MS; Fecher L; Gajewski TF; Gastman B; Lawson DH; Lutzky J; McDermott DF; Margolin KA; Mehnert JM; Pavlick AC; Richards JM; Rubin KM; Sharfman W; Silverstein S; Slingluff CL; Sondak VK; Tarhini AA; Thompson JA; Urba WJ; White RL; Whitman ED; Hodi FS; Kaufman HL
J Immunother Cancer; 2018 May; 6(1):44. PubMed ID: 29848375
[TBL] [Abstract][Full Text] [Related]
2. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
Kaufman HL; Kirkwood JM; Hodi FS; Agarwala S; Amatruda T; Bines SD; Clark JI; Curti B; Ernstoff MS; Gajewski T; Gonzalez R; Hyde LJ; Lawson D; Lotze M; Lutzky J; Margolin K; McDermott DF; Morton D; Pavlick A; Richards JM; Sharfman W; Sondak VK; Sosman J; Steel S; Tarhini A; Thompson JA; Titze J; Urba W; White R; Atkins MB
Nat Rev Clin Oncol; 2013 Oct; 10(10):588-98. PubMed ID: 23982524
[TBL] [Abstract][Full Text] [Related]
3. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
Pavlick AC; Ariyan CE; Buchbinder EI; Davar D; Gibney GT; Hamid O; Hieken TJ; Izar B; Johnson DB; Kulkarni RP; Luke JJ; Mitchell TC; Mooradian MJ; Rubin KM; Salama AK; Shirai K; Taube JM; Tawbi HA; Tolley JK; Valdueza C; Weiss SA; Wong MK; Sullivan RJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852736
[TBL] [Abstract][Full Text] [Related]
4. [Guidelines for clinical practice: Standards, Options and Recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National Federation of Cancer Campaign Centers. French Dermatology Society. Update of the 1995 Consensus Conference and the 1998 Standards, Options, and Recommendations].
Négrier S; Saiag P; Guillot B; Verola O; Avril MF; Bailly C; Cupissol D; Dalac S; Danino A; Dreno B; Grob JJ; Leccia MT; Renaud-Vilmer C; Bosquet L; ;
Ann Dermatol Venereol; 2005 Dec; 132(12 Pt 2):10S3-10S85. PubMed ID: 16521904
[No Abstract] [Full Text] [Related]
5. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Brahmer JR; Govindan R; Anders RA; Antonia SJ; Sagorsky S; Davies MJ; Dubinett SM; Ferris A; Gandhi L; Garon EB; Hellmann MD; Hirsch FR; Malik S; Neal JW; Papadimitrakopoulou VA; Rimm DL; Schwartz LH; Sepesi B; Yeap BY; Rizvi NA; Herbst RS
J Immunother Cancer; 2018 Jul; 6(1):75. PubMed ID: 30012210
[TBL] [Abstract][Full Text] [Related]
6. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma.
Basile D; Lisanti C; Pizzichetta MA; Baldo P; Fornasier G; Lo Re F; Corona G; Puglisi F
Recent Pat Anticancer Drug Discov; 2019; 14(3):203-225. PubMed ID: 31362664
[TBL] [Abstract][Full Text] [Related]
7. Clinical and molecular insights into BCG immunotherapy for melanoma.
Kremenovic M; Schenk M; Lee DJ
J Intern Med; 2020 Dec; 288(6):625-640. PubMed ID: 32128919
[TBL] [Abstract][Full Text] [Related]
8. [Clinical practice guideline: 2005 update of recommendations for the management of patients with cutaneous melanoma without distant metastases (summary report)].
Négrier S; Saiag P; Guillot B; Verola O; Avril MF; Bailly C; Cupissol D; Dalac S; Danino A; Dreno B; Grob JJ; Leccia MT; Renaud-Vilmer C; Bosquet L; ; ; ; ; ; ; ;
Bull Cancer; 2006 Apr; 93(4):371-84. PubMed ID: 16714227
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
10. Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement.
Peach H; Board R; Cook M; Corrie P; Ellis S; Geh J; King P; Laitung G; Larkin J; Marsden J; Middleton M; Moncrieff M; Nathan P; Powell B; Pritchard-Jones R; Rodwell S; Steven N; Lorigan P
J Plast Reconstr Aesthet Surg; 2020 Jan; 73(1):36-42. PubMed ID: 31477493
[TBL] [Abstract][Full Text] [Related]
11. The use of electrochemotherapy in combination with immunotherapy in the treatment of metastatic melanoma: a focused review.
Goggins CA; Khachemoune A
Int J Dermatol; 2019 Aug; 58(8):865-870. PubMed ID: 30479009
[TBL] [Abstract][Full Text] [Related]
12. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
Kamat AM; Bellmunt J; Galsky MD; Konety BR; Lamm DL; Langham D; Lee CT; Milowsky MI; O'Donnell MA; O'Donnell PH; Petrylak DP; Sharma P; Skinner EC; Sonpavde G; Taylor JA; Abraham P; Rosenberg JE
J Immunother Cancer; 2017 Aug; 5(1):68. PubMed ID: 28807024
[TBL] [Abstract][Full Text] [Related]
13. Future Directions and Challenges Facing Intralesional Immunotherapy With Talimogene Laherparepvec for Advanced Melanoma.
Queen D; Samie FH; Zeitouni NC
Dermatol Surg; 2021 Jan; 47(1):132-133. PubMed ID: 31574028
[No Abstract] [Full Text] [Related]
14. i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol.
Hyatt A; Gough K; Murnane A; Au-Yeung G; Dawson T; Pearson E; Dhillon H; Sandhu S; Williams N; Paton E; Billett A; Traill A; Andersen H; Beedle V; Milne D
BMJ Open; 2020 Feb; 10(2):e036059. PubMed ID: 32114479
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy For Advanced Skin Cancer.
Morgado-Carrasco D; Terc F; Ertekin SS; Ferrandiz L
Actas Dermosifiliogr (Engl Ed); 2019; 110(1):53-56. PubMed ID: 29548489
[No Abstract] [Full Text] [Related]
16. Systemic Therapies for Advanced Melanoma.
Bomar L; Senithilnathan A; Ahn C
Dermatol Clin; 2019 Oct; 37(4):409-423. PubMed ID: 31466582
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
18. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma -- a clinical update.
Trinh VA; Joseph J; Hwu WJ
Discov Med; 2018 Jan; 25(135):31-40. PubMed ID: 29466692
[TBL] [Abstract][Full Text] [Related]
19. Considering adjuvant therapy for stage II melanoma.
Poklepovic AS; Luke JJ
Cancer; 2020 Mar; 126(6):1166-1174. PubMed ID: 31869447
[TBL] [Abstract][Full Text] [Related]
20. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
